View Future GrowthMINAPHARM Pharmaceuticals 過去の業績過去 基準チェック /16MINAPHARM Pharmaceuticalsの収益は年間平均-32.7%の割合で減少していますが、 Pharmaceuticals業界の収益は年間 増加しています。収益は年間22.2% 20.6%割合で 増加しています。 MINAPHARM Pharmaceuticalsの自己資本利益率は0.7%であり、純利益率は0.1%です。主要情報-32.70%収益成長率-30.84%EPS成長率Pharmaceuticals 業界の成長9.80%収益成長率20.59%株主資本利益率0.74%ネット・マージン0.10%前回の決算情報31 Dec 2025最近の業績更新Reported Earnings • Jun 14Full year 2025 earnings released: EPS: ج.م0.59 (vs ج.م11.58 in FY 2024)Full year 2025 results: EPS: ج.م0.59 (down from ج.م11.58 in FY 2024). Revenue: ج.م6.44b (up 14% from FY 2024). Net income: ج.م40.2m (down 69% from FY 2024). Profit margin: 0.6% (down from 2.3% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 44% per year, which means it is well ahead of earnings.Reported Earnings • Jun 04First quarter 2024 earnings released: EPS: ج.م0.37 (vs ج.م3.49 in 1Q 2023)First quarter 2024 results: EPS: ج.م0.37 (down from ج.م3.49 in 1Q 2023). Revenue: ج.م984.3m (up 1.2% from 1Q 2023). Net income: ج.م4.05m (down 90% from 1Q 2023). Profit margin: 0.4% (down from 4.0% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has increased by 31% per year, which means it is well ahead of earnings.Reported Earnings • Aug 31Second quarter 2023 earnings released: EPS: ج.م7.92 (vs ج.م11.31 in 2Q 2022)Second quarter 2023 results: EPS: ج.م7.92 (down from ج.م11.31 in 2Q 2022). Revenue: ج.م1.07b (up 24% from 2Q 2022). Net income: ج.م87.7m (down 35% from 2Q 2022). Profit margin: 8.2% (down from 16% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Jun 01First quarter 2023 earnings released: EPS: ج.م3.86 (vs ج.م10.24 in 1Q 2022)First quarter 2023 results: EPS: ج.م3.86 (down from ج.م10.24 in 1Q 2022). Revenue: ج.م972.2m (up 22% from 1Q 2022). Net income: ج.م49.9m (down 60% from 1Q 2022). Profit margin: 5.1% (down from 16% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 46% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Dec 04Third quarter 2022 earnings released: EPS: ج.م17.41 (vs ج.م8.40 in 3Q 2021)Third quarter 2022 results: EPS: ج.م17.41 (up from ج.م8.40 in 3Q 2021). Revenue: ج.م984.6m (up 30% from 3Q 2021). Net income: ج.م184.0m (up 80% from 3Q 2021). Profit margin: 19% (up from 14% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.Reported Earnings • Apr 04Full year 2020 earnings releasedThe company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: ج.م2.36b (up 15% from FY 2019). Net income: ج.م300.8m (up 113% from FY 2019). Profit margin: 13% (up from 6.9% in FY 2019). The increase in margin was driven by higher revenue.すべての更新を表示Recent updatesReported Earnings • Jun 14Full year 2025 earnings released: EPS: ج.م0.59 (vs ج.م11.58 in FY 2024)Full year 2025 results: EPS: ج.م0.59 (down from ج.م11.58 in FY 2024). Revenue: ج.م6.44b (up 14% from FY 2024). Net income: ج.م40.2m (down 69% from FY 2024). Profit margin: 0.6% (down from 2.3% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 44% per year, which means it is well ahead of earnings.Board Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • May 06MINAPHARM Pharmaceuticals, Annual General Meeting, Jun 02, 2026MINAPHARM Pharmaceuticals, Annual General Meeting, Jun 02, 2026, at 15:00 Egypt Standard Time. Location: cairo Egyptお知らせ • May 27MINAPHARM Pharmaceuticals, Annual General Meeting, Jun 18, 2025MINAPHARM Pharmaceuticals, Annual General Meeting, Jun 18, 2025, at 15:00 Egypt Standard Time. Location: tenth of ramadan EgyptNew Risk • May 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Egyptian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.7x net interest cover). Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Market cap is less than US$100m (ج.م2.34b market cap, or US$46.7m).Board Change • May 14No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.New Risk • Sep 11New major risk - Revenue and earnings growthEarnings have declined by 2.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.4x net interest cover). Earnings have declined by 2.6% per year over the past 5 years. Minor Risk Market cap is less than US$100m (ج.م1.83b market cap, or US$37.8m).Reported Earnings • Jun 04First quarter 2024 earnings released: EPS: ج.م0.37 (vs ج.م3.49 in 1Q 2023)First quarter 2024 results: EPS: ج.م0.37 (down from ج.م3.49 in 1Q 2023). Revenue: ج.م984.3m (up 1.2% from 1Q 2023). Net income: ج.م4.05m (down 90% from 1Q 2023). Profit margin: 0.4% (down from 4.0% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has increased by 31% per year, which means it is well ahead of earnings.New Risk • Mar 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (11% operating cash flow to total debt). High level of non-cash earnings (47% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (ج.م2.88b market cap, or US$60.2m).Valuation Update With 7 Day Price Move • Jan 25Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ج.م249, the stock trades at a trailing P/E ratio of 6x. Average trailing P/E is 8x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 219% over the past three years.Valuation Update With 7 Day Price Move • Nov 21Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ج.م238, the stock trades at a trailing P/E ratio of 5.7x. Average trailing P/E is 7x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 223% over the past three years.Reported Earnings • Aug 31Second quarter 2023 earnings released: EPS: ج.م7.92 (vs ج.م11.31 in 2Q 2022)Second quarter 2023 results: EPS: ج.م7.92 (down from ج.م11.31 in 2Q 2022). Revenue: ج.م1.07b (up 24% from 2Q 2022). Net income: ج.م87.7m (down 35% from 2Q 2022). Profit margin: 8.2% (down from 16% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Jun 29Upcoming dividend of ج.م2.80 per share at 1.3% yieldEligible shareholders must have bought the stock before 06 July 2023. Payment date: 10 July 2023. Payout ratio is a comfortable 6.2% but the company is not cash flow positive. Trailing yield: 1.3%. Lower than top quartile of Egyptian dividend payers (7.5%). Lower than average of industry peers (3.5%).Reported Earnings • Jun 01First quarter 2023 earnings released: EPS: ج.م3.86 (vs ج.م10.24 in 1Q 2022)First quarter 2023 results: EPS: ج.م3.86 (down from ج.م10.24 in 1Q 2022). Revenue: ج.م972.2m (up 22% from 1Q 2022). Net income: ج.م49.9m (down 60% from 1Q 2022). Profit margin: 5.1% (down from 16% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 46% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • May 22Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ج.م227, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 4x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 261% over the past three years.Reported Earnings • Dec 04Third quarter 2022 earnings released: EPS: ج.م17.41 (vs ج.م8.40 in 3Q 2021)Third quarter 2022 results: EPS: ج.م17.41 (up from ج.م8.40 in 3Q 2021). Revenue: ج.م984.6m (up 30% from 3Q 2021). Net income: ج.م184.0m (up 80% from 3Q 2021). Profit margin: 19% (up from 14% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Jul 20Investor sentiment improved over the past weekAfter last week's 16% share price gain to ج.م164, the stock trades at a trailing P/E ratio of 4.4x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 118% over the past three years.Upcoming Dividend • Jun 20Upcoming dividend of ج.م2.92 per shareEligible shareholders must have bought the stock before 27 June 2022. Payment date: 29 June 2022. Payout ratio is a comfortable 7.8% but the company is not cash flow positive. Trailing yield: 1.9%. Lower than top quartile of Egyptian dividend payers (11%). Lower than average of industry peers (4.2%).Valuation Update With 7 Day Price Move • May 31Investor sentiment improved over the past weekAfter last week's 15% share price gain to ج.م150, the stock trades at a trailing P/E ratio of 4.1x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 95% over the past three years.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Jan 10Investor sentiment improved over the past weekAfter last week's 18% share price gain to ج.م128, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 75% over the past three years.Upcoming Dividend • May 19Upcoming dividend of ج.م2.70 per shareEligible shareholders must have bought the stock before 26 May 2021. Payment date: 30 May 2021. Trailing yield: 2.5%. Lower than top quartile of Egyptian dividend payers (8.2%). Lower than average of industry peers (4.2%).Valuation Update With 7 Day Price Move • Apr 28Investor sentiment improved over the past weekAfter last week's 16% share price gain to ج.م99.28, the stock trades at a trailing P/E ratio of 4.1x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 18% over the past three years.Valuation Update With 7 Day Price Move • Apr 07Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ج.م84.88, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 1.0% over the past three years.Reported Earnings • Apr 04Full year 2020 earnings releasedThe company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: ج.م2.36b (up 15% from FY 2019). Net income: ج.م300.8m (up 113% from FY 2019). Profit margin: 13% (up from 6.9% in FY 2019). The increase in margin was driven by higher revenue.Valuation Update With 7 Day Price Move • Feb 08Investor sentiment improved over the past weekAfter last week's 34% share price gain to ج.م111, the stock is trading at a trailing P/E ratio of 5x, up from the previous P/E ratio of 3.7x. This compares to an average P/E of 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders over the past three years are 68%.Is New 90 Day High Low • Feb 03New 90-day high: ج.م86.57The company is up 15% from its price of ج.م75.13 on 05 November 2020. The Egyptian market is also up 15% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Pharmaceuticals industry, which is up 4.0% over the same period.Is New 90 Day High Low • Jan 12New 90-day high: ج.م85.89The company is up 15% from its price of ج.م75.00 on 14 October 2020. The Egyptian market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is flat over the same period.Reported Earnings • Dec 04Third quarter 2020 earnings released: EPS ج.م6.32The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ج.م590.8m (up 17% from 3Q 2019). Net income: ج.م77.6m (up 247% from 3Q 2019). Profit margin: 13% (up from 4.4% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.Is New 90 Day High Low • Nov 30New 90-day high: ج.م80.50The company is up 4.0% from its price of ج.م77.15 on 01 September 2020. The Egyptian market is up 2.0% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Pharmaceuticals industry, which is also up 4.0% over the same period.お知らせ • Jul 31Shaheer Wafik Saad El Bardisy acquired an additional 10% stake in MINAPHARM Pharmaceuticals (CASE:MIPH) for approximately EGP 100 million.Shaheer Wafik Saad El Bardisy acquired an additional 10% stake in MINAPHARM Pharmaceuticals (CASE:MIPH) for approximately EGP 100 million on July 26, 2020. Shaheer Wafik Saad El Bardisy bought 1.2 million shares and increased his stake to 10.89%. Shaheer Wafik Saad El Bardisy completed the acquisition of an additional 10% stake in MINAPHARM Pharmaceuticals (CASE:MIPH) on July 26, 2020.収支内訳MINAPHARM Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史CASE:MIPH 収益、費用、利益 ( )EGP Millions日付収益収益G+A経費研究開発費31 Dec 256,43871,05722530 Sep 256,9241121,11319230 Jun 256,9362211,09516831 Mar 256,28816698614231 Dec 245,60012886713130 Sep 244,423-12773714930 Jun 243,916-25970115631 Mar 243,904-15474015431 Dec 233,892-5572615130 Sep 234,02528165312730 Jun 234,0034616039831 Mar 233,7945295257631 Dec 223,6215904725930 Sep 223,4425444564630 Jun 223,2124674294631 Mar 223,0324544014731 Dec 213,0054483864630 Sep 212,9184223775330 Jun 212,7543983574631 Mar 212,5833253374331 Dec 202,3612853273930 Sep 202,2002713274030 Jun 202,1152163123931 Mar 202,0801743194031 Dec 192,0511413113930 Sep 191,917863104830 Jun 191,936673045231 Mar 191,948813065931 Dec 181,9191162916530 Sep 181,9281562586830 Jun 181,8201862476531 Mar 181,7171982205431 Dec 171,6461752095330 Sep 171,493652034630 Jun 171,325551934131 Mar 171,190351794631 Dec 161,035331733930 Sep 161,023861523230 Jun 161,019971463431 Mar 161,0011101452931 Dec 15966831402630 Sep 15916851382930 Jun 158856113728質の高い収益: MIPHは 高品質の収益 を持っています。利益率の向上: MIPHの現在の純利益率 (0.1%)は、昨年(2.3%)よりも低くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: MIPHの収益は過去 5 年間で年間32.7%減少しました。成長の加速: MIPHは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。収益対業界: MIPHは過去 1 年間で収益成長率がマイナス ( -94.8% ) となったため、 Pharmaceuticals業界平均 ( 31.5% ) と比較することが困難です。株主資本利益率高いROE: MIPHの 自己資本利益率 ( 0.7% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/21 13:25終値2026/06/21 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋MINAPHARM Pharmaceuticals 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Jun 14Full year 2025 earnings released: EPS: ج.م0.59 (vs ج.م11.58 in FY 2024)Full year 2025 results: EPS: ج.م0.59 (down from ج.م11.58 in FY 2024). Revenue: ج.م6.44b (up 14% from FY 2024). Net income: ج.م40.2m (down 69% from FY 2024). Profit margin: 0.6% (down from 2.3% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 44% per year, which means it is well ahead of earnings.
Reported Earnings • Jun 04First quarter 2024 earnings released: EPS: ج.م0.37 (vs ج.م3.49 in 1Q 2023)First quarter 2024 results: EPS: ج.م0.37 (down from ج.م3.49 in 1Q 2023). Revenue: ج.م984.3m (up 1.2% from 1Q 2023). Net income: ج.م4.05m (down 90% from 1Q 2023). Profit margin: 0.4% (down from 4.0% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has increased by 31% per year, which means it is well ahead of earnings.
Reported Earnings • Aug 31Second quarter 2023 earnings released: EPS: ج.م7.92 (vs ج.م11.31 in 2Q 2022)Second quarter 2023 results: EPS: ج.م7.92 (down from ج.م11.31 in 2Q 2022). Revenue: ج.م1.07b (up 24% from 2Q 2022). Net income: ج.م87.7m (down 35% from 2Q 2022). Profit margin: 8.2% (down from 16% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Jun 01First quarter 2023 earnings released: EPS: ج.م3.86 (vs ج.م10.24 in 1Q 2022)First quarter 2023 results: EPS: ج.م3.86 (down from ج.م10.24 in 1Q 2022). Revenue: ج.م972.2m (up 22% from 1Q 2022). Net income: ج.م49.9m (down 60% from 1Q 2022). Profit margin: 5.1% (down from 16% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 46% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Dec 04Third quarter 2022 earnings released: EPS: ج.م17.41 (vs ج.م8.40 in 3Q 2021)Third quarter 2022 results: EPS: ج.م17.41 (up from ج.م8.40 in 3Q 2021). Revenue: ج.م984.6m (up 30% from 3Q 2021). Net income: ج.م184.0m (up 80% from 3Q 2021). Profit margin: 19% (up from 14% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Apr 04Full year 2020 earnings releasedThe company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: ج.م2.36b (up 15% from FY 2019). Net income: ج.م300.8m (up 113% from FY 2019). Profit margin: 13% (up from 6.9% in FY 2019). The increase in margin was driven by higher revenue.
Reported Earnings • Jun 14Full year 2025 earnings released: EPS: ج.م0.59 (vs ج.م11.58 in FY 2024)Full year 2025 results: EPS: ج.م0.59 (down from ج.م11.58 in FY 2024). Revenue: ج.م6.44b (up 14% from FY 2024). Net income: ج.م40.2m (down 69% from FY 2024). Profit margin: 0.6% (down from 2.3% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 44% per year, which means it is well ahead of earnings.
Board Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • May 06MINAPHARM Pharmaceuticals, Annual General Meeting, Jun 02, 2026MINAPHARM Pharmaceuticals, Annual General Meeting, Jun 02, 2026, at 15:00 Egypt Standard Time. Location: cairo Egypt
お知らせ • May 27MINAPHARM Pharmaceuticals, Annual General Meeting, Jun 18, 2025MINAPHARM Pharmaceuticals, Annual General Meeting, Jun 18, 2025, at 15:00 Egypt Standard Time. Location: tenth of ramadan Egypt
New Risk • May 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Egyptian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.7x net interest cover). Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Market cap is less than US$100m (ج.م2.34b market cap, or US$46.7m).
Board Change • May 14No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
New Risk • Sep 11New major risk - Revenue and earnings growthEarnings have declined by 2.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.4x net interest cover). Earnings have declined by 2.6% per year over the past 5 years. Minor Risk Market cap is less than US$100m (ج.م1.83b market cap, or US$37.8m).
Reported Earnings • Jun 04First quarter 2024 earnings released: EPS: ج.م0.37 (vs ج.م3.49 in 1Q 2023)First quarter 2024 results: EPS: ج.م0.37 (down from ج.م3.49 in 1Q 2023). Revenue: ج.م984.3m (up 1.2% from 1Q 2023). Net income: ج.م4.05m (down 90% from 1Q 2023). Profit margin: 0.4% (down from 4.0% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has increased by 31% per year, which means it is well ahead of earnings.
New Risk • Mar 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (11% operating cash flow to total debt). High level of non-cash earnings (47% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (ج.م2.88b market cap, or US$60.2m).
Valuation Update With 7 Day Price Move • Jan 25Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ج.م249, the stock trades at a trailing P/E ratio of 6x. Average trailing P/E is 8x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 219% over the past three years.
Valuation Update With 7 Day Price Move • Nov 21Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ج.م238, the stock trades at a trailing P/E ratio of 5.7x. Average trailing P/E is 7x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 223% over the past three years.
Reported Earnings • Aug 31Second quarter 2023 earnings released: EPS: ج.م7.92 (vs ج.م11.31 in 2Q 2022)Second quarter 2023 results: EPS: ج.م7.92 (down from ج.م11.31 in 2Q 2022). Revenue: ج.م1.07b (up 24% from 2Q 2022). Net income: ج.م87.7m (down 35% from 2Q 2022). Profit margin: 8.2% (down from 16% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Jun 29Upcoming dividend of ج.م2.80 per share at 1.3% yieldEligible shareholders must have bought the stock before 06 July 2023. Payment date: 10 July 2023. Payout ratio is a comfortable 6.2% but the company is not cash flow positive. Trailing yield: 1.3%. Lower than top quartile of Egyptian dividend payers (7.5%). Lower than average of industry peers (3.5%).
Reported Earnings • Jun 01First quarter 2023 earnings released: EPS: ج.م3.86 (vs ج.م10.24 in 1Q 2022)First quarter 2023 results: EPS: ج.م3.86 (down from ج.م10.24 in 1Q 2022). Revenue: ج.م972.2m (up 22% from 1Q 2022). Net income: ج.م49.9m (down 60% from 1Q 2022). Profit margin: 5.1% (down from 16% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 46% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • May 22Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ج.م227, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 4x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 261% over the past three years.
Reported Earnings • Dec 04Third quarter 2022 earnings released: EPS: ج.م17.41 (vs ج.م8.40 in 3Q 2021)Third quarter 2022 results: EPS: ج.م17.41 (up from ج.م8.40 in 3Q 2021). Revenue: ج.م984.6m (up 30% from 3Q 2021). Net income: ج.م184.0m (up 80% from 3Q 2021). Profit margin: 19% (up from 14% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Jul 20Investor sentiment improved over the past weekAfter last week's 16% share price gain to ج.م164, the stock trades at a trailing P/E ratio of 4.4x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 118% over the past three years.
Upcoming Dividend • Jun 20Upcoming dividend of ج.م2.92 per shareEligible shareholders must have bought the stock before 27 June 2022. Payment date: 29 June 2022. Payout ratio is a comfortable 7.8% but the company is not cash flow positive. Trailing yield: 1.9%. Lower than top quartile of Egyptian dividend payers (11%). Lower than average of industry peers (4.2%).
Valuation Update With 7 Day Price Move • May 31Investor sentiment improved over the past weekAfter last week's 15% share price gain to ج.م150, the stock trades at a trailing P/E ratio of 4.1x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 95% over the past three years.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Jan 10Investor sentiment improved over the past weekAfter last week's 18% share price gain to ج.م128, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 75% over the past three years.
Upcoming Dividend • May 19Upcoming dividend of ج.م2.70 per shareEligible shareholders must have bought the stock before 26 May 2021. Payment date: 30 May 2021. Trailing yield: 2.5%. Lower than top quartile of Egyptian dividend payers (8.2%). Lower than average of industry peers (4.2%).
Valuation Update With 7 Day Price Move • Apr 28Investor sentiment improved over the past weekAfter last week's 16% share price gain to ج.م99.28, the stock trades at a trailing P/E ratio of 4.1x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 18% over the past three years.
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ج.م84.88, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 1.0% over the past three years.
Reported Earnings • Apr 04Full year 2020 earnings releasedThe company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: ج.م2.36b (up 15% from FY 2019). Net income: ج.م300.8m (up 113% from FY 2019). Profit margin: 13% (up from 6.9% in FY 2019). The increase in margin was driven by higher revenue.
Valuation Update With 7 Day Price Move • Feb 08Investor sentiment improved over the past weekAfter last week's 34% share price gain to ج.م111, the stock is trading at a trailing P/E ratio of 5x, up from the previous P/E ratio of 3.7x. This compares to an average P/E of 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders over the past three years are 68%.
Is New 90 Day High Low • Feb 03New 90-day high: ج.م86.57The company is up 15% from its price of ج.م75.13 on 05 November 2020. The Egyptian market is also up 15% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Pharmaceuticals industry, which is up 4.0% over the same period.
Is New 90 Day High Low • Jan 12New 90-day high: ج.م85.89The company is up 15% from its price of ج.م75.00 on 14 October 2020. The Egyptian market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is flat over the same period.
Reported Earnings • Dec 04Third quarter 2020 earnings released: EPS ج.م6.32The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ج.م590.8m (up 17% from 3Q 2019). Net income: ج.م77.6m (up 247% from 3Q 2019). Profit margin: 13% (up from 4.4% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
Is New 90 Day High Low • Nov 30New 90-day high: ج.م80.50The company is up 4.0% from its price of ج.م77.15 on 01 September 2020. The Egyptian market is up 2.0% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Pharmaceuticals industry, which is also up 4.0% over the same period.
お知らせ • Jul 31Shaheer Wafik Saad El Bardisy acquired an additional 10% stake in MINAPHARM Pharmaceuticals (CASE:MIPH) for approximately EGP 100 million.Shaheer Wafik Saad El Bardisy acquired an additional 10% stake in MINAPHARM Pharmaceuticals (CASE:MIPH) for approximately EGP 100 million on July 26, 2020. Shaheer Wafik Saad El Bardisy bought 1.2 million shares and increased his stake to 10.89%. Shaheer Wafik Saad El Bardisy completed the acquisition of an additional 10% stake in MINAPHARM Pharmaceuticals (CASE:MIPH) on July 26, 2020.